Monoclonal Antibody Therapy
Novel COVID-19 monoclonal antibody therapy
Currently two monoclonal antibody therapies have been authorized under a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA). The limited supply, and restrictions imposed by the FDA, authorize the use of these treatments to only a small subset of the COVID-19 positive cases. In Utah, the product received from the Federal Government is estimated to treat between 2-5% of the eligible population.
In addition to Eligibility Criteria, there are a number of Inclusion Criteria as defined by the EUA that specify who is eligible for this novel treatment.